The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them.

These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends:

• Drug resistance and Interactions
• Antibiotic Abuse
• Antibiotic Cycling
• Addressing Market Trends
• Antibiotic Use in Agriculture
• Antibiotic Education
• Children and Bacterial Resistance
• The Elderly and Bacterial Resistance
• Compromised Individuals and Bacterial Resistance
• Screening Hospital Patients
• Side Effects of Antibiotics
• Partnerships and Alliances
• Environment and Drug Resistance
• Methicillin Resistant Staphylococcus Aureus

The title is part of Kalorama Information's Anti-Infectives series, which represents a total decison and problem-solving support tool for decision makers in the pharmaceutical industry dealing with anti-infectives, or those assisting customers or looking at investments in this area.

Because of antibiotic resitance and other changing dynamics, knowledge of issues and trends is necessary to operate the antibacterials market. In this, the second volume of Kalorama Information's Anti-Infective Markets series, the antibacterial drug market is broken down into seven general categories based on drug class:

• cephalosporins
• macrolides
• penicillins
• quinolones
• sulfonamides
• tetracyclines
• other misc. antibiotics

There is a significant trend shift occuring in the antibacterials market since Kalorama Information's last edition in 2005. Anti-Infectives Vol. II: Antibacterials covers that shift in detail. For each marketplace segment, Market Size, Growth and Share are provided, and revenue is forecasted to 2011 are provided. Current products are discussed and new pipeline products are assessed. This report also breaks out marketplace data by Infection Type the only publication to do so. In total, over 100 Tables and Figures provide accessible data on this growing market, a depth of coverage unsurpassed by any competitive study.

The following companies are profiled as part of this report:

• Abbott Laboratories
• AstraZeneca
• Bayer Schering Pharma
• Cubist Pharmaceuticals
• Daiichi Sankyo
• GlaxoSmithKline
• Johnson & Johnson Group
• King Pharmaceuticals
• Merck & Company, Inc.
• Pfizer, Inc.
• Roche
• Sanofi-Aventis
• Wyeth

Related Reports:

Smoking Cessation: World Markets
Nov 1, 2008 - KLI1646594 - $3,500.00

Glucose Testing Markets
Nov 1, 2008 - KLI1911068 - $1,995.00

Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
Nov 1, 2008 - KLI1816262 - $3,995.00

Worldwide In Vitro Diagnostics Market Research Bundle (Worldwide Market for In Vitro Diagnostic Tests, SNP Genotyping Markets, Companion Diagnostics, Testing Services Markets)
Oct 1, 2008 - KLI1927625 - $7,995.00

Kalorama Medical Device Market Research Bundle: Infusion Pumps, Minimally Invasive Devices, Syringes, Hip and Knee Implants, Respiratory Equipment, Asian Device Markets, OEM Contract Manufacturing, Reusable Equipment, Catheters)
Oct 1, 2008 - KLI1927457 - $9,995.00

HIV: Markets for Diagnostics and Therapeutics
Oct 1, 2008 - KLI1646600 - $3,500.00

Minimally Invasive Surgical Devices, World Market
Sep 1, 2008 - KLI1614100 - $3,500.00

Facial Rejuvenation Markets Worldwide
Aug 1, 2008 - KLI1190879 - $3,500.00

IVD Market Research Supplement : Testing Services Markets, SNP Analysis, DNA Sequencing, Retail Clinics, Companion Diagnostics
Aug 1, 2008 - KLI1836320 - $8,995.00

Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing: A Roadmap to Diagnostics in the 21st Century
Aug 1, 2008 - KLI1806317 - $3,500.00